Dong Celia M, Guo Audrey S, To Anthea, Chan Kannie W Y, Chow Aviva S F, Bian Liming, Leong Alex T L, Wu Ed X
Annu Int Conf IEEE Eng Med Biol Soc. 2020 Jul;2020:1100-1103. doi: 10.1109/EMBC44109.2020.9176013.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia. Early stage β-amyloid oligomers (AβOs) and late stage Aβ plaques are the pathological hallmarks of AD brains. AβOs are known to be more neurotoxic and contribute to neuronal damage. Most current approaches are focused on detecting Aβ plaques, which occurs at the late stage of AD, and are limited by poor sensitivity and/or contrast agent toxicity. In previous studies, we developed a new curcumin-conjugated magnetic nanoparticle (Cur-MNPs) to target the Aβ pathologies. In this study, we investigate the in vivo feasibility of this novel Cur-MNPs to detect Aβ pathologies at the early and late stages of AD in transgenic AD mice and perform immunohistochemical examinations to validate the specific targeting of various form of Aβ pathologies.
阿尔茨海默病（AD）是一种退行性脑疾病，也是痴呆最常见的病因。早期的β-淀粉样寡聚体（AβOs）和晚期的Aβ斑块是AD大脑的病理特征。已知AβOs具有更强的神经毒性，并会导致神经元损伤。目前大多数方法都集中于检测出现在AD晚期的Aβ斑块，且受灵敏度低和/或造影剂毒性的限制。在先前的研究中，我们开发了一种新的姜黄素共轭磁性纳米颗粒（Cur-MNPs）来靶向Aβ病变。在本研究中，我们探究了这种新型Cur-MNPs在转基因AD小鼠体内检测AD早期和晚期Aβ病变的可行性，并进行免疫组化检查以验证其对各种形式Aβ病变的特异性靶向作用。
